Trials / Completed
CompletedNCT02579681
Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012
Single Country Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis Patients Treated With BG00012
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 221 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective(s) of the study are to assess the BG00012 (dimethyl fumarate) treatment effect on cognition over 2 year period in RRMS patients. The secondary objectives of this study are to further assess BG00012 treatment effect on cognition, predictors of cognitive impairment, clinical efficacy, and patient reported outcomes (PRO): depression, fatigue, quality of life, and work and social life activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dimethyl fumarate | dimethyl fumarate administered as per the arm description |
Timeline
- Start date
- 2014-04-30
- Primary completion
- 2016-12-21
- Completion
- 2016-12-21
- First posted
- 2015-10-20
- Last updated
- 2017-04-27
Locations
18 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT02579681. Inclusion in this directory is not an endorsement.